化学療法誘発性好中球減少症治療の世界市場レポート 2025年

化学療法誘発性好中球減少症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.3％で7億6,000万米ドルに成長します。予測期間における成長の原動力は、標的好中球減少症治療薬に対する需要の高まり、がん研究開発への投資の拡大、外来治療への注目の高まり、バイオシミラーの使用拡大、感染予防に対する意識の高まりなどです。予測期間中に予想される主な動向としては、長時間作用型顆粒球コロニー刺激因子（G-CSF）製剤の開発、併用療法の増加、在宅ケアソリューションへの嗜好の高まり、バイオシミラーの承認急増、デジタルヘルスモニタリングツールの統合などが挙げられます。

がん罹患率の増加が化学療法誘発性好中球減少症治療市場の成長を牽引すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散によって特徴づけられる疾患群です。がん患者の増加は、人口の高齢化が主な原因であり、高齢者は時間の経過とともに蓄積された遺伝子変異や免疫機能の低下により、がんにかかりやすくなるからです。化学療法誘発性好中球減少症治療は、免疫系をサポートすることで感染リスクを軽減し、患者が化学療法を中断することなく継続できるようにします。この治療は患者の安全性を高め、治療成績を向上させ、生活の質を高めます。例えば、2024年7月、オーストラリア保健福祉研究所（Australian Institute of Health and Welfare）は、オーストラリアにおけるがんの診断数が2022年には160,570例に上り、2021年の156,781例から3,789例増加したと報告しました。したがって、がんの罹患率の増加が化学療法誘発性好中球減少症治療市場の成長を牽引しています。

化学療法誘発性好中球減少症治療市場の企業は、患者の利便性を向上させ、投与回数を減らし、治療アドヒアランスを高めるために、長時間作用型製剤などの革新的な製品の開発に注力しています。長時間作用型製剤は、有効成分を長期間にわたって徐々に放出するように設計された製剤であり、頻繁な投与の必要性を低減します。例えば、2023年12月、コーヘラス・バイオサイエンシズ社は、新規のすぐに使える体内注射器であるUdenyca OnbodyのFDA承認を取得しました。この装置は化学療法後約27時間後にペグフィルグラスチムの長時間作用型製剤を投与するため、翌日の注射が不要となります。Udenyca Onbodyは、化学療法による好中球減少症の予防的治療をタイムリーに行うことで、患者体験を向上させるとともに、通院回数を減らし、服薬アドヒアランスを高めます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界化学療法誘発性好中球減少症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の化学療法誘発性好中球減少症治療市場：成長率分析
• 世界の化学療法誘発性好中球減少症治療市場の実績：規模と成長、2019～2024年
• 世界の化学療法誘発性好中球減少症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界化学療法誘発性好中球減少症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の化学療法誘発性好中球減少症治療市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗生物質療法
• 顆粒球コロニー刺激因子療法（G-CSF）
• 顆粒球輸血
• その他のタイプ
• 世界の化学療法誘発性好中球減少症治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮下
• 静脈内
• 世界の化学療法誘発性好中球減少症治療市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 固形腫瘍
• 造血悪性腫瘍
• その他の適応症
• 世界の化学療法誘発性好中球減少症治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の化学療法誘発性好中球減少症治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 在宅ケア設定
• 世界の化学療法誘発性好中球減少症治療市場：抗生物質療法の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 広域スペクトル抗生物質
• 狭域スペクトル抗生物質
• 予防的抗生物質
• 世界の化学療法誘発性好中球減少症治療市場：顆粒球コロニー刺激因子療法（G-CSF）の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• フィルグラスチム
• ペグフィルグラスチム
• レノグラスチム
• 世界の化学療法誘発性好中球減少症治療市場：顆粒球輸血の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 同種顆粒球輸血
• 自己顆粒球輸血
• 世界の化学療法誘発性好中球減少症治療市場：その他の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗真菌療法
• 幹細胞療法
• 免疫調節療法

第7章 地域別・国別分析

• 世界の化学療法誘発性好中球減少症治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の化学療法誘発性好中球減少症治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 化学療法誘発性好中球減少症治療市場：競合情勢
• 化学療法誘発性好中球減少症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Biogen Inc.
• Baxter Inteational
• Fresenius Kabi
• Eisai Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Exelixis Inc.
• Biocon Biologics Limited
• Coherus BioSciences Inc.
• G1 Therapeutics
• Enzychem Lifesciences Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 化学療法誘発性好中球減少症治療市場、2029年：新たな機会を提供する国
• 化学療法誘発性好中球減少症治療市場、2029年：新たな機会を提供するセグメント
• 化学療法誘発性好中球減少症治療市場、2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chemotherapy-induced neutropenia treatment refers to medical management designed to assist cancer patients whose white blood cell levels decrease after chemotherapy. This treatment reduces the duration and severity of neutropenia, helping prevent infections. It typically involves the use of growth factors and adjustments to chemotherapy doses, while early intervention promotes schedule adherence and improves patient outcomes.

The primary types of chemotherapy-induced neutropenia treatment include antibiotic therapy, granulocyte colony-stimulating factor therapy (G-CSF), granulocyte transfusions, and other treatments. Antibiotic therapy involves the use of antibiotics to treat or prevent bacterial infections by either killing bacteria or inhibiting their growth. The treatment is administered through subcutaneous or intravenous methods. Key indications for this treatment include solid tumors, hematological malignancies, and other related conditions. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. The main end users of these treatments are hospitals, specialty clinics, and homecare settings.

The chemotherapy-induced neutropenia treatment market research report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced neutropenia treatment market statistics, including chemotherapy-induced neutropenia treatment industry global market size, regional shares, competitors with a chemotherapy-induced neutropenia treatment market share, detailed chemotherapy-induced neutropenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced neutropenia treatment industry. This chemotherapy-induced neutropenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced neutropenia treatment market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth during the historic period can be attributed to increasing cancer incidence rates, rising chemotherapy adoption, a growing geriatric population, high hospitalization rates due to infections, and an expanding oncology drug pipeline.

The chemotherapy-induced neutropenia treatment market size is expected to see strong growth in the next few years. It will grow to $0.76 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period is driven by the rising demand for targeted neutropenia therapies, growing investment in oncology research and development, an increasing focus on outpatient care, expanded use of biosimilars, and heightened awareness of infection prevention. Key trends expected in the forecast period include the development of long-acting granulocyte colony-stimulating factor (G-CSF) agents, increasing use of combination therapies, a rising preference for home-based care solutions, a surge in biosimilar approvals, and the integration of digital health monitoring tools.

The increasing incidence of cancer is expected to drive the growth of the chemotherapy-induced neutropenia treatment market. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer cases is largely attributed to the aging population, as older individuals are more susceptible to cancer due to accumulated genetic mutations and weakened immune function over time. Chemotherapy-induced neutropenia treatment helps reduce infection risks by supporting the immune system, allowing patients to continue chemotherapy with fewer interruptions. This treatment improves overall patient safety, enhances treatment outcomes, and boosts quality of life. For example, in July 2024, the Australian Institute of Health and Welfare reported that cancer diagnoses in Australia rose to 160,570 in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the growing incidence of cancer is driving the growth of the chemotherapy-induced neutropenia treatment market.

Companies in the chemotherapy-induced neutropenia treatment market are focusing on developing innovative products, such as long-acting formulations, to improve patient convenience, reduce dosing frequency, and enhance treatment adherence. Long-acting formulations are drug preparations designed to release active ingredients gradually over an extended period, reducing the need for frequent administration. For instance, in December 2023, Coherus BioSciences Inc. received FDA approval for Udenyca Onbody, a novel, ready-to-use on-body injector. This device delivers a long-acting formulation of pegfilgrastim approximately 27 hours after chemotherapy, eliminating the need for a next-day injection. Udenyca Onbody improves the patient experience by ensuring timely prophylactic treatment for chemotherapy-induced neutropenia while reducing clinic visits and enhancing adherence.

In July 2022, Evive Biotech Ltd., a Singapore-based biopharmaceutical company, partnered with APOGEPHA Arzneimittel GmbH to commercialize Efbemalenograstim alfa (F-627) in Germany and Switzerland. This collaboration aims to expand access to F-627 for preventing chemotherapy-induced neutropenia, improve patient outcomes, and strengthen APOGEPHA's position in the oncology supportive care market. APOGEPHA Arzneimittel GmbH, based in Germany, offers chemotherapy-induced neutropenia treatment through its product Ryzneuta (Efbemalenograstim alfa).

Major players in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy's Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation.

North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chemotherapy-induced neutropenia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chemotherapy-induced neutropenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy-induced neutropenia treatment market consists of revenues earned by entities by providing services such as neutrophil count monitoring, chemotherapy dose management, patient education and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced neutropenia treatment market also includes sales of biologics, biosimilars, and supportive care devices such as auto-injectors and on-body delivery systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced neutropenia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy-induced neutropenia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy-induced neutropenia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Antibiotic Therapy; Granulocyte Colony-Stimulating Factor Therapy (G-CSF); Granulocyte Transfusion; Other Types
• 2) By Route of Administration: Subcutaneous; Intravenous
• 3) By Indication: Solid Tumors; Hematological Malignancies; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Specialty Clinics; Homecare Settings
• Subsegments:
• 1) By Antibiotic Therapy: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics; Prophylactic Antibiotics
• 2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim; Pegfilgrastim; Lenograstim
• 3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion; Autologous Granulocyte Transfusion
• 4) By Other Types: Antifungal Therapy; Stem Cell Therapy; Immunomodulatory Therapy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; GSK plc; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Neutropenia Treatment Market Characteristics

3. Chemotherapy-Induced Neutropenia Treatment Market Trends And Strategies

4. Chemotherapy-Induced Neutropenia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Chemotherapy-Induced Neutropenia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chemotherapy-Induced Neutropenia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chemotherapy-Induced Neutropenia Treatment Market Growth Rate Analysis
• 5.4. Global Chemotherapy-Induced Neutropenia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chemotherapy-Induced Neutropenia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chemotherapy-Induced Neutropenia Treatment Total Addressable Market (TAM)

6. Chemotherapy-Induced Neutropenia Treatment Market Segmentation

• 6.1. Global Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotic Therapy
• Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
• Granulocyte Transfusion
• Other Types
• 6.2. Global Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• 6.3. Global Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solid Tumors
• Hematological Malignancies
• Other Indications
• 6.4. Global Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare Settings
• 6.6. Global Chemotherapy-Induced Neutropenia Treatment Market, Sub-Segmentation Of Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics
• Prophylactic Antibiotics
• 6.7. Global Chemotherapy-Induced Neutropenia Treatment Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor Therapy (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Filgrastim
• Pegfilgrastim
• Lenograstim
• 6.8. Global Chemotherapy-Induced Neutropenia Treatment Market, Sub-Segmentation Of Granulocyte Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Allogeneic Granulocyte Transfusion
• Autologous Granulocyte Transfusion
• 6.9. Global Chemotherapy-Induced Neutropenia Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifungal Therapy
• Stem Cell Therapy
• Immunomodulatory Therapy

7. Chemotherapy-Induced Neutropenia Treatment Market Regional And Country Analysis

• 7.1. Global Chemotherapy-Induced Neutropenia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chemotherapy-Induced Neutropenia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Market

• 8.1. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy-Induced Neutropenia Treatment Market

• 9.1. China Chemotherapy-Induced Neutropenia Treatment Market Overview
• 9.2. China Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy-Induced Neutropenia Treatment Market

• 10.1. India Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy-Induced Neutropenia Treatment Market

• 11.1. Japan Chemotherapy-Induced Neutropenia Treatment Market Overview
• 11.2. Japan Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy-Induced Neutropenia Treatment Market

• 12.1. Australia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy-Induced Neutropenia Treatment Market

• 13.1. Indonesia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy-Induced Neutropenia Treatment Market

• 14.1. South Korea Chemotherapy-Induced Neutropenia Treatment Market Overview
• 14.2. South Korea Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy-Induced Neutropenia Treatment Market

• 15.1. Western Europe Chemotherapy-Induced Neutropenia Treatment Market Overview
• 15.2. Western Europe Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy-Induced Neutropenia Treatment Market

• 16.1. UK Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy-Induced Neutropenia Treatment Market

• 17.1. Germany Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy-Induced Neutropenia Treatment Market

• 18.1. France Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy-Induced Neutropenia Treatment Market

• 19.1. Italy Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy-Induced Neutropenia Treatment Market

• 20.1. Spain Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy-Induced Neutropenia Treatment Market

• 21.1. Eastern Europe Chemotherapy-Induced Neutropenia Treatment Market Overview
• 21.2. Eastern Europe Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy-Induced Neutropenia Treatment Market

• 22.1. Russia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy-Induced Neutropenia Treatment Market

• 23.1. North America Chemotherapy-Induced Neutropenia Treatment Market Overview
• 23.2. North America Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy-Induced Neutropenia Treatment Market

• 24.1. USA Chemotherapy-Induced Neutropenia Treatment Market Overview
• 24.2. USA Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy-Induced Neutropenia Treatment Market

• 25.1. Canada Chemotherapy-Induced Neutropenia Treatment Market Overview
• 25.2. Canada Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy-Induced Neutropenia Treatment Market

• 26.1. South America Chemotherapy-Induced Neutropenia Treatment Market Overview
• 26.2. South America Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy-Induced Neutropenia Treatment Market

• 27.1. Brazil Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy-Induced Neutropenia Treatment Market

• 28.1. Middle East Chemotherapy-Induced Neutropenia Treatment Market Overview
• 28.2. Middle East Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy-Induced Neutropenia Treatment Market

• 29.1. Africa Chemotherapy-Induced Neutropenia Treatment Market Overview
• 29.2. Africa Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chemotherapy-Induced Neutropenia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy-Induced Neutropenia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Chemotherapy-Induced Neutropenia Treatment Market Competitive Landscape
• 30.2. Chemotherapy-Induced Neutropenia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy-Induced Neutropenia Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Amgen Inc.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Astellas Pharma Inc.
• 31.6. Biogen Inc.
• 31.7. Baxter Inteational
• 31.8. Fresenius Kabi
• 31.9. Eisai Co. Ltd.
• 31.10. Dr. Reddy's Laboratories Ltd.
• 31.11. Exelixis Inc.
• 31.12. Biocon Biologics Limited
• 31.13. Coherus BioSciences Inc.
• 31.14. G1 Therapeutics
• 31.15. Enzychem Lifesciences Corporation

32. Global Chemotherapy-Induced Neutropenia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Neutropenia Treatment Market

34. Recent Developments In The Chemotherapy-Induced Neutropenia Treatment Market

35. Chemotherapy-Induced Neutropenia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Chemotherapy-Induced Neutropenia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chemotherapy-Induced Neutropenia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chemotherapy-Induced Neutropenia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer